Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment

Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard, Robert Kirsner

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical clinical presentations. Its pathophysiology is complex and not fully explained. Recent information regarding the genetic basis of PG and the role of auto-inflammation provides a better understanding of the disease and new therapeutic targets. PG equally affects patients of both sexes and of any age. Uncontrolled cutaneous neutrophilic inflammation is the cornerstone in a genetically predisposed individual. Multimodality management is often required to reduce inflammation, optimize wound healing, and treat underlying disease. A gold standard for the management of PG does not exist and high-level evidence is limited. Multiple factors must be taken into account when deciding on the optimum treatment for individual patients: location, number and size of lesion/ulceration(s), extracutaneous involvement, presence of associated disease, cost, and side effects of treatment, as well as patient comorbidities and preferences. Refractory and rapidly progressive cases require early initiation of systemic therapy. Newer targeted therapies represent a promising pathway for the management of PG, and the main focus of this review is the management and evidence supporting the role of new targeted therapies in PG.

Original languageEnglish (US)
Pages (from-to)355-372
Number of pages18
JournalAmerican Journal of Clinical Dermatology
Volume18
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Pyoderma Gangrenosum
Inflammation
Therapeutics
Cost of Illness
Patient Preference
Wound Healing
Comorbidity
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Pyoderma Gangrenosum : An Update on Pathophysiology, Diagnosis and Treatment. / Alavi, Afsaneh; French, Lars E.; Davis, Mark D.; Brassard, Alain; Kirsner, Robert.

In: American Journal of Clinical Dermatology, Vol. 18, No. 3, 01.06.2017, p. 355-372.

Research output: Contribution to journalReview article

Alavi, Afsaneh ; French, Lars E. ; Davis, Mark D. ; Brassard, Alain ; Kirsner, Robert. / Pyoderma Gangrenosum : An Update on Pathophysiology, Diagnosis and Treatment. In: American Journal of Clinical Dermatology. 2017 ; Vol. 18, No. 3. pp. 355-372.
@article{cef02d4c433241d6bfa0376793c07271,
title = "Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment",
abstract = "Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical clinical presentations. Its pathophysiology is complex and not fully explained. Recent information regarding the genetic basis of PG and the role of auto-inflammation provides a better understanding of the disease and new therapeutic targets. PG equally affects patients of both sexes and of any age. Uncontrolled cutaneous neutrophilic inflammation is the cornerstone in a genetically predisposed individual. Multimodality management is often required to reduce inflammation, optimize wound healing, and treat underlying disease. A gold standard for the management of PG does not exist and high-level evidence is limited. Multiple factors must be taken into account when deciding on the optimum treatment for individual patients: location, number and size of lesion/ulceration(s), extracutaneous involvement, presence of associated disease, cost, and side effects of treatment, as well as patient comorbidities and preferences. Refractory and rapidly progressive cases require early initiation of systemic therapy. Newer targeted therapies represent a promising pathway for the management of PG, and the main focus of this review is the management and evidence supporting the role of new targeted therapies in PG.",
author = "Afsaneh Alavi and French, {Lars E.} and Davis, {Mark D.} and Alain Brassard and Robert Kirsner",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s40257-017-0251-7",
language = "English (US)",
volume = "18",
pages = "355--372",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Pyoderma Gangrenosum

T2 - An Update on Pathophysiology, Diagnosis and Treatment

AU - Alavi, Afsaneh

AU - French, Lars E.

AU - Davis, Mark D.

AU - Brassard, Alain

AU - Kirsner, Robert

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical clinical presentations. Its pathophysiology is complex and not fully explained. Recent information regarding the genetic basis of PG and the role of auto-inflammation provides a better understanding of the disease and new therapeutic targets. PG equally affects patients of both sexes and of any age. Uncontrolled cutaneous neutrophilic inflammation is the cornerstone in a genetically predisposed individual. Multimodality management is often required to reduce inflammation, optimize wound healing, and treat underlying disease. A gold standard for the management of PG does not exist and high-level evidence is limited. Multiple factors must be taken into account when deciding on the optimum treatment for individual patients: location, number and size of lesion/ulceration(s), extracutaneous involvement, presence of associated disease, cost, and side effects of treatment, as well as patient comorbidities and preferences. Refractory and rapidly progressive cases require early initiation of systemic therapy. Newer targeted therapies represent a promising pathway for the management of PG, and the main focus of this review is the management and evidence supporting the role of new targeted therapies in PG.

AB - Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical clinical presentations. Its pathophysiology is complex and not fully explained. Recent information regarding the genetic basis of PG and the role of auto-inflammation provides a better understanding of the disease and new therapeutic targets. PG equally affects patients of both sexes and of any age. Uncontrolled cutaneous neutrophilic inflammation is the cornerstone in a genetically predisposed individual. Multimodality management is often required to reduce inflammation, optimize wound healing, and treat underlying disease. A gold standard for the management of PG does not exist and high-level evidence is limited. Multiple factors must be taken into account when deciding on the optimum treatment for individual patients: location, number and size of lesion/ulceration(s), extracutaneous involvement, presence of associated disease, cost, and side effects of treatment, as well as patient comorbidities and preferences. Refractory and rapidly progressive cases require early initiation of systemic therapy. Newer targeted therapies represent a promising pathway for the management of PG, and the main focus of this review is the management and evidence supporting the role of new targeted therapies in PG.

UR - http://www.scopus.com/inward/record.url?scp=85019160306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019160306&partnerID=8YFLogxK

U2 - 10.1007/s40257-017-0251-7

DO - 10.1007/s40257-017-0251-7

M3 - Review article

C2 - 28224502

AN - SCOPUS:85019160306

VL - 18

SP - 355

EP - 372

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 3

ER -